Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating the effects of methotrexate, a drug approved for conditions like arthritis and psoriasis, for adults with moderate to severe atopic dermatitisan ongoing skin condition causing irritation, redness, and itchiness. This phase 3 randomized, controlled clinical trial aims to evaluate the safety and effectiveness of methotrexate compared to a placebo for participants whose condition does not improve with topical treatments. The study is sponsored by medac GmbH and uses a double-blind design. Participants will receive weekly subcutaneous injections of methotrexate at 20 mg for 16 to 24 weeks, with a possible dose reduction to 15 mg if needed due to intolerance. The comparator group will receive matching placebo injections on the same schedule. The trial follows a parallel-group, randomized approach to compare these two treatment arms while monitoring their effects on atopic dermatitis. During the study, participants will be assessed regularly using various tools, including the Eczema Area and Severity Index EASI, Scoring Atopic Dermatitis SCORAD, Investigator Global Assessment IGA, Pruritus Numerical Rating Scale NRS, and quality of life measures. Safety will be monitored through adverse event tracking and laboratory tests at multiple visits through week 33. The main outcome is the proportion of participants achieving at least a 75% improvement in EASI score by week 16. Participants are expected to comply with study procedures and attend scheduled visits throughout the trial period.
Actively Recruiting
Researchers are evaluating the long-term safety of two drugs, Deucravacitinib and Ustekinumab, in adults with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic treatments. This study is designed to compare these treatments over an extended period, focusing on cardiovascular health and other safety outcomes. The study is sponsored by Bristol-Myers Squibb and is a Phase 3b4 randomized, open-label trial. Participants are randomly assigned to receive either Deucravacitinib or Ustekinumab at specified doses on scheduled days. The study spans up to 5 years, during which participants will be monitored closely for cardiovascular events and other safety outcomes. Treatment adherence and effects will be regularly assessed throughout this long-term safety study. During the study, participants will undergo various evaluations including monitoring for major cardiovascular events such as heart attacks and strokes, other cardiovascular complications, and laboratory assessments including liver function and lipid panels. Researchers will also track serious adverse events and overall mortality up to 60 days after the last dose. This comprehensive monitoring ensures participant safety and gathers essential data on the long-term effects of the treatments over the studys duration, which lasts until January 2031.